

## 4.0.03 DOC Cmte minutes

### Lung cancer Committee meeting

**Date:** 16/05/2018

**Location:** NICE offices Manchester

**Minutes:** Final



<b>Committee members present:</b>	
Gary McVeigh (GM) (Chair)	Present for all
Douglas West (DW) (Vice-Chair)	Present for all
Shahzeena Aslam (SA)	Present for all
Elaine Borg (EB)	From partway through item 1
Lynn Campbell (LC)	Present for all
Sujal Desai (SD)	Present for all
Jesme Fox (JF)	Present until partway through item 8
Tom Haswell (TH)	Present for all
Sue Maughn (SM)	Present until partway through item 8
Neal Navani (NN)	Present for all
Andrea McIver (AM)	Present for all
Rhiannon Walters-Davies (RW)	Present until partway through item 8
Nigel Westwood (NWW)	Present for all
Clifford Wyn Jones (CW)	Present until partway through item 8

<b>In attendance:</b>		
Sohaib Ashraf (SAS)	NICE – Technical Analyst Health Economics	Present for all
Rupert Franklin (RF)	NICE – Commissioning Manager	Present for all
Ross Maconachie (RM)	NICE – Technical Advisor Health Economics	Present for all
Toby Mercer (TM)	NICE – Technical Analyst	Present for all
Caroline Mulvihill (CM)	NICE – Technical Advisor	Present for all
Vonda Murray (VM)	NICE – Project Manager	Present for all

#### 4.0.03 DOC Cmte minutes

<b>Apologies:</b>	
Steven Connor	Committee member
Joanna Perkin	NICE – Digital Editor
Sue Spiers	NICE – Associate Director Guideline Updates Team

#### Item 1

- Welcome
- Objectives
- Declarations of interest
- Minutes of the last meeting

#### Item 1

The Chair welcomed the Committee members, and attendees to the 6<sup>th</sup> committee meeting on lung cancer.

The Chair went through the agenda, and outlined the objectives for the meeting. The minutes were reviewed from Gcomm 5; Wednesday 4<sup>th</sup> April 2018. The minutes were agreed to be an accurate record.

The DOI register was made available to the Chair, and committee. The Chair reviewed the DOI register. A number of new declarations was made, and these are noted below. The DOI's were considered by the Chair. It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

Attendee	Declaration	Action
Shahzeena Aslam	Attended a British Thoracic Oncology Group neuroendocrine/small cell lung cancer essential update meeting 18/04/18. Free event.	Direct non-financial
Elaine Borg	Honorarium received for lecture at EBUS masterclass June 2018	Direct financial  Related to RQ1.2 & RQ1.2  Exclude from any future recommendation making for RQ1.2 & RQ1.2
Lynn Campbell	Attended an evening meeting sponsored by Roche about	Direct non-financial

#### 4.0.03 DOC Cmte minutes

	immunotherapy on the 3rd May 2018. General info about immunotherapy drugs in practice. Refreshments provided	(non-specific) Not specific to any topic covered in the scope of the guideline
Lynn Campbell	Attended the British Thoracic Oncology Group, education day, 18th April 2018, on Neuroendocrine tumours. Free event	Direct non-financial (non-specific) Not specific to any topic covered in the scope of the guideline
Jesme Fox	Participated in a short Advisory Board teleconference 08.04.18, with Boehringer Ingelheim. No honorarium or expenses were paid. The topics discussed were not relevant to Committee discussions (non-medical interventions).	Direct non-financial (non-specific) Not specific to any topic covered in the scope of the guideline
Andrea McIvor	Attended the National lung nurse forum for nurses (NLCFN) workshop 14 <sup>th</sup> & 15 <sup>th</sup> May. Accommodation and refreshments provided by NLCFN.	Direct financial (non-specific) No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Neal Navani	Presented at the American Thoracic Society Conference; 'Interventional Pulmonology' in San Diego. Travel and accommodation paid by Oncimmune Ltd. No payment received.	Direct financial (non-specific) No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. Reasonable travel and subsistence
Rhiannon Walters-Davies	Attended a meeting on how to horizon forecast for upcoming drugs (all drugs not yet approved). The meeting was held in March 2018 supported by the Association of the British Pharmaceutical Industry.	Direct non-financial (non-specific) Not specific to any topic covered in the scope of

#### 4.0.03 DOC Cmte minutes

		the guideline
Douglas West	Part of a panel for Public Health England to support the writing of a report; Perspectives in Lung Cancer Care (organisation of lung cancer services and identifying areas of best practice in Europe that could be applied to the NHS.). Bristol Myers Squibb will pay travel expenses for the 3 meetings	Direct non-financial (non-specific)  Not specific to any topic covered in the scope of the guideline
<b>Item 2</b> Lay members slot		
<b>Item 2</b> Lay members given the opportunity to ask questions of NICE staff relating to the review questions.		
<b>Item 3</b> RQ3.1 What is the clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage NSCLC?  <ul style="list-style-type: none"> <li>• Presentation of network meta-analysis</li> <li>• Discuss economics</li> <li>• Agree recommendations</li> </ul>		
<b>Item 3</b> RM presented to the committee the results of the network meta-analysis for, what is the clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage NSCLC. The committee discussed the evidence presented, and reviewed and drafted updated recommendations accordingly pending the full results of the health economic model and additional statistical analyses. The underpinning assumptions of these additional analyses were agreed by the committee.		
<b>Item 4</b> RQ 1.3 What is the clinical and cost effectiveness of routine MRI or CT of the brain in the management of people with lung cancer prior to radical therapy with curative intent?  <ul style="list-style-type: none"> <li>• Update on health economic modelling</li> </ul>		
<b>Item 4</b> SAS and RM provided an update on the health economic modelling for cost effectiveness of routine MRI or CT of the brain in the management of people with lung cancer prior to radical therapy with curative intent. The committee asked		

#### 4.0.03 DOC Cmte minutes

questions, and discussed.
<b>Item 5</b> Clinical presentation (background to RQ 3.2)
<b>Item 5</b> SA provided a clinical introduction on the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0)
<b>Item 6</b> RQ3.2 What is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0)? <ul style="list-style-type: none"><li>• Presentation of clinical evidence</li></ul>
<b>Item 6</b> TM provided an overview of the current related recommendations. Outlined the agreed protocol, and results of the search and sift. The evidence was presented to the committee on, the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0).
<b>Item 7</b> <ul style="list-style-type: none"><li>• NICE Pathway</li></ul>
<b>Item 7</b> Due to time constraints the NICE Pathway presentation will be moved to a later meeting.
<b>Item 8</b> RQ3.2 What is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0)? <ul style="list-style-type: none"><li>• Present published health economics papers</li><li>• Presentation of clinical evidence</li><li>• Agree recommendations</li></ul>
<b>Item 8</b> SAS presented the health economic evidence for what is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0). The committee discussed the evidence presented, and reviewed and updated recommendations accordingly.
<b>Item 9</b> <ul style="list-style-type: none"><li>• AOB</li></ul>
<b>Item 9</b> No other business to discuss

#### 4.0.03 DOC Cmte minutes

<b>Item 10</b>
<ul style="list-style-type: none"><li>• Summary and next steps</li></ul>
<b>Item 10</b>
The Chair thanked the committee for their hard work and contribution. The next committee meeting is GComm 7. The committee meeting on day2 will start at the early time of 09:00, and finish at 16:00



**Date of next meeting:** Monday 18th June 2018 (10:00 to 17:00)

Tuesday 19th June 2018 (09:00 to 16:00)

**Location of next meeting:** NICE Offices – London